Higher Throughput Behavioral Screening of Cognitive Enhancers

认知增强剂的更高通量行为筛选

• 批准号: 7169555
• 负责人: Daniela Brunner
• 金额: $ 20万
• 依托单位: PSYCHOGENICS, INC.
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-01-15 至 2007-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7169555
• 关键词: Acute; Affect; Age; Algorithms; Area; Attention; Attention Deficit Disorder; Basic Behavioral Science; Behavior; Behavioral; Binding; Bioinformatics; Central Nervous System Diseases; Cognition; Cognitive; Computer Vision Systems; Data; Data Set; Dementia; Development; Evaluation; Human; Impaired cognition; Learning; Libraries; Link; Machine Learning; Measures; Mouse Strains; Movement; Mus; National Institute of Mental Health; Neurosciences; Nootropic Agents; Performance; Pharmaceutical Preparations; Phase; Population; Process; Protocols documentation; Research; Research Personnel; Rodent; Schizophrenia; Screening procedure; Shapes; Short-Term Memory; Signal Transduction; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Somatotype; Standards of Weights and Measures; System; Testing; Therapeutic Index; Time; Training; United States; Validation; base; behavior measurement; behavior test; brain behavior; cognitive function; concept; drug discovery; improved; in vivo; innovation; novel; programs; response; tool

DESCRIPTION (provided by applicant): This application is submitted in response to NIMH research topic J1, neuroscience and basic behavioral science in the SBIR solicitation and PA-04-086, development of high throughput tools for brain and behavior. We aim to alleviate the bottleneck in drug discovery for cognitive dysfunction with CognoCube(tm), an automated high-throughput system of behavioral analysis of cognitive function. CognoCube(tm) will comprise innovative automated testing, computer vision, and machine-learning algorithms to capture and integrate behavioral effects of drugs affecting cognitive function. CognoCube will capture many cognitive domains of high degree of homology between humans and rodents that are relevant in CNS disorders such as schizophrenia, dementia, attention-deficit disorder and ageing. This system will provide rapid and accurate indices of the therapeutic potential of novel cognitive enhancers. Phase I will be focused on proof of concept, namely, capture of behaviors relevant to targeted cognitive domains, sensitivity to pharmacological manipulation and robust bioinformatic analysis. The CognoCube(tm) system will expand its capacity during Phase II of the project to be able to assess a library of 1000 compounds per year. With libraries chosen to provide a high likelihood of CNS activity we expect to be able to detect up to a dozen new compounds per year with CNS activity in the area of cognition. Those compounds will be further assessed with standard tests of cognition and their mechanism of action will be studied through pharmacological means and binding profiling. Commercial value: The population that could benefit from new and improved cognitive enhancers is estimated at more than 30 million in the United States alone. Major challenges for drug discovery in this area include the lack of reliable and efficient in vivo testing systems. Although standardized objective test batteries have been developed for evaluation of human cognition, there is no such standard battery for rodents. Our automated cognitive testing system for mice will provide superior reliability, greater statistical power and higher throughput than standard cognitive tests and, with its power to screen libraries in vivo, will discover novel compounds with efficacy in cognition.

描述（由申请人提供）：本申请是为了响应NIMH研究主题J1，SBIR征集中的神经科学和基础行为科学以及PA-04-086，大脑和行为的高通量工具的开发而提交的。我们的目标是缓解认知功能障碍药物发现的瓶颈与CognoCube（TM），认知功能的行为分析的自动化高通量系统。CognoCube（TM）将包括创新的自动化测试、计算机视觉和机器学习算法，以捕捉和整合影响认知功能的药物的行为效应。CognoCube将捕获人类和啮齿动物之间高度同源的许多认知领域，这些领域与中枢神经系统疾病（如精神分裂症、痴呆症、注意力缺陷障碍和衰老）相关。该系统将为新型认知增强剂的治疗潜力提供快速准确的指标。第一阶段将侧重于概念验证，即捕获与目标认知领域相关的行为，对药理学操作的敏感性和强大的生物信息学分析。CognoCube（TM）系统将在项目的第二阶段扩大其容量，每年能够评估1000种化合物的库。随着库的选择，以提供一个高的可能性中枢神经系统的活动，我们预计能够检测到多达十几个新的化合物，每年与中枢神经系统的活动在认知领域。这些化合物将进一步评估与标准测试的认知和他们的作用机制将通过药理学手段和结合分析进行研究。商业价值：据估计，仅在美国，可以从新的和改进的认知增强剂中受益的人口就超过3000万。这一领域药物发现的主要挑战包括缺乏可靠和有效的体内测试系统。虽然已经开发了用于评估人类认知的标准化客观测试组合，但没有用于啮齿动物的标准组合。我们的小鼠自动认知测试系统将提供比标准认知测试更上级的可靠性，更大的统计能力和更高的通量，并且凭借其在体内筛选文库的能力，将发现具有认知功效的新型化合物。